# Antibiotic_use_by_species_and_nutraceutical_opportunity.xlsx

## Sheet: Sheet1

| Species                   |   Approx_change_since_2011_% |   Approx_change_since_2015_% | Regulatory_pressure_level          |   Nutraceutical_opportunity_score_1_5 | Key_nutraceutical_axes                                   |
|:--------------------------|-----------------------------:|-----------------------------:|:-----------------------------------|--------------------------------------:|:---------------------------------------------------------|
| Poultry                   |                          -60 |                          -30 | Very high (AGP bans, EU focus)     |                                     5 | Gut integrity, microbiome, coccidiosis support, immune   |
| Swine                     |                          -50 |                          -25 | High (ZnO phaseout, stewardship)   |                                     5 | Weaning gut health, postbiotics, immune, stress          |
| Cattle                    |                          -25 |                          -10 | Medium (targeted use, stewardship) |                                     3 | Mastitis support, immunity, transition cow metabolism    |
| Other ruminants / rabbits |                          -35 |                          -15 | Medium                             |                                     3 | Enteric health, resilience                               |
| Aquaculture               |                          -20 |                          -10 | Variable / emerging                |                                     4 | Immunity, microbiome, stress, survival                   |
| Companion animals         |                          -12 |                           -5 | Low to medium (stewardship focus)  |                                     3 | Dermatology, gut, mobility, urinary, ear disease adjunct |

